Key result
Class Ic antiarrhythmic agents demonstrated an efficacy rate of 42% in patients with drug-resistant paroxysmal atrial fibrillation/flutter and 100% in those with drug-resistant atrial tachycardia.
Why the study?
Do class Ic antiarrhythmic agents prevent recurrence in patients with drug-resistant paroxysmal atrial fibrillation/flutter and repetitive atrial tachycardia?
Observational (n=116)
No
Do class Ic antiarrhythmic agents prevent recurrence in patients with drug-resistant paroxysmal atrial fibrillation/flutter and repetitive atrial tachycardia?
Class Ic antiarrhythmic agents are effective for drug-resistant paroxysmal atrial fibrillation, particularly in patients without underlying disease, with good cardiac function, and within 1 year of onset, as well as for repetitive atrial tachycardia.
May support select refractory atrial tachycardia cases; leaves open randomized confirmation for paroxysmal AF/flutter.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sugi et al. (1995) conducted an observational in Drug-resistant paroxysmal atrial fibrillation, atrial flutter, and atrial tachycardia (n=116). Class Ic antiarrhythmic agents (flecainide, pilsicainide, propafenone) was evaluated on Efficacy (complete suppression of arrhythmia attacks for at least 2 weeks). Class Ic antiarrhythmic agents demonstrated an efficacy rate of 42% in patients with drug-resistant paroxysmal atrial fibrillation/flutter and 100% in those with drug-resistant atrial tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: